SpringerLink
Log in

Serum pepsinogen and osteopontin for gastric cancer screening

  • Gastrointestinal Cancer
  • Published:
Chinese Journal of Cancer Research

Abstract

Objective

To investigate the value of combined assay of serum pepsinogen (PG) and osteopontin (OPN) levels for gastric cancer screening.

Methods

Fasting serum pepsinogen I, II and OPN concentration were measured by ELISA in 570 subjects. The cut off points for PG and OPN were determined using ROC.

Results

Using serum PGI concentration ≤80 ng/ml, I:II ration ≤5.0 and OPN concentration ≥34 ng/ml or ≥30.44 ng/ml (based on ROC) for gastric cancer screening had superior specificity, positive and negative predictive values compared with PG or OPN screening only. The sensitive and specificity of combining serum PG and OPN assay were both more than 70% compared with PG or OPN screening alone.

Conclusion

Combining serum PG and OPN assay for gastric cancer screening is superior to PG or OPN level only. This may be a new method for gastric cancer mass screening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fahey MT, Hamada GS, Nishimoto IN, et al. Ethnic differences in serum pepsinogen levels among Japanese and non-Japanese Brazilian gastric cancer patients and controls [J]. Cancer Detect Prev 2000; 24:564–571.

    PubMed  CAS  Google Scholar 

  2. Kokkola A, Louhimo J, Puolakkainen P, et al. Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma [J]. World J Gastroenterol 2005; 11:1032–1036.

    PubMed  CAS  Google Scholar 

  3. Miki K, Ichinose M, Ishikawa KB, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer [J]. Jpn J Cancer Res 1993; 84:1086–1090.

    PubMed  CAS  Google Scholar 

  4. O’Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques [J]. Arterioscler Thromb 1994; 14:1648–1656.

    PubMed  CAS  Google Scholar 

  5. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and Osteopontin (Eta-1) [J]. Science 1996; 271:509–512.

    Article  PubMed  CAS  Google Scholar 

  6. Bayless KJ, Davis GE. Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human Osteopontin [J]. J Biol Chem 2001; 276:13483–13489.

    Article  PubMed  CAS  Google Scholar 

  7. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene [J]. Br J Cancer 2000; 83:156–163.

    Article  PubMed  CAS  Google Scholar 

  8. Fedarko NS, Jain A, Karadag A, et al. SIBLING interactions with complement factor H and pro-matrixmetalloproteinases [G]. In: Third International Conference on Osteopontin and SIBLING proteins. Aan Antonio, TX. 2002.

  9. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of Osteopontin in interstitial fibrosis and apoptosis [J]. Kidney Int 1999; 56:571–580.

    Article  PubMed  CAS  Google Scholar 

  10. Fedarko NS, Fohr B, Robey PG, et al. Factor H binding to bone sialoprotein and Osteopontin enables tumor cell evasion of complement-mediated attack [J]. J Biol Chem 2000; 275:1666–1672.

    Article  Google Scholar 

  11. Oates AJ, Barraclough R, Rudland PS. The identification of Osteopontin as a metastasis-related gene product in a rodent mammary tumour model [J]. Oncogene 1996; 13:97–104.

    PubMed  CAS  Google Scholar 

  12. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression [J]. Clin Cancer Res 1999; 5:2271–2277.

    PubMed  CAS  Google Scholar 

  13. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein Osteopontin in human breast cancer [J]. Cancer Res 2002; 62:3417–3427.

    PubMed  CAS  Google Scholar 

  14. Hotte SJ, Winquist EW, Stitt L, et al. Plasma Osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma [J]. Cancer 2002; 95:506–512.

    Article  PubMed  CAS  Google Scholar 

  15. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling [J]. J Natl Cancer Inst 2002; 94:513–521.

    PubMed  CAS  Google Scholar 

  16. Fedarko NS, Jain A, Karadag A, et al. Elevated serum one sialoprotein and osteopontin in colon, breast, prostate, and lung cancer [J]. Clin Cancer Res 2001; 7:4060–4066.

    PubMed  CAS  Google Scholar 

  17. Webb MP, Hengels KJ, Moller H, et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. Gastroenterology 1994; 107:1335–1344.

    PubMed  CAS  Google Scholar 

  18. Tsugane S, Kabuto M, Imai H, et al. Helicobacter pylori, dietary factors, and atrophic gastritis in five Japanese populations with different gastric cancer mortality [J]. Cancer Causes Control 1993; 4:297–305.

    Article  PubMed  CAS  Google Scholar 

  19. Hamahata M. A study on the management of accuracy by the close examination in the gastric mass survey [J]. Igaku Kenkyu 1993; 63:33–47.

    PubMed  CAS  Google Scholar 

  20. Maruyama T, Noda Y, Kumamoto Y. Estimation of frequency, population doses and stochastic risks in stomach mass screening examination in Japan, 1980. Nippon Igaku Hoshasen Gakkai Zasshi 1987; 47:971–982.

    PubMed  CAS  Google Scholar 

  21. Sitas F, Smallwood R, Jewell D, et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological makers of chronic atrophic gastritis [J]. Cancer Epidemiol Biomarkers Pre 1993; 2:119–123.

    CAS  Google Scholar 

  22. Stemmermann GN, Samloff IM, Nomura AM, et al. Serum pepsinogen I and II and stomach cancer [J]. Clin Chim Acta 1987; 163:191–198.

    Article  PubMed  CAS  Google Scholar 

  23. Kodoi A, Yoshihara M, Sumii K, et al. Serum pepsinogen in screening for gastric cancer [J]. J Gastroenterol 1995; 30:452–460.

    Article  PubMed  CAS  Google Scholar 

  24. Yuan Yuan, Zhang Lian. Comprehensive prevention and treatment for high risk population from high risk areas of gastric cancer in China [J]. Bulletin Chin Cancer (in Chin) 2001; 10:139–142.

    Google Scholar 

  25. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study [J]. Gut 2005; 54:764–768.

    Article  PubMed  CAS  Google Scholar 

  26. Denhardt DT, Lopez CA, Rollo EE, et al. Osteopontin-induced modifications of cellular functions [J]. Ann N Y Acad Sci 1995; 760:127–142.

    Article  PubMed  CAS  Google Scholar 

  27. Devoll RE, Li W, Woods KV, et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity [J]. J Oral Pathol Med 1999; 28:97–101.

    Article  PubMed  CAS  Google Scholar 

  28. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions [J]. FASEB J 1993; 7:1475–1482.

    PubMed  CAS  Google Scholar 

  29. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma [J]. Cancer Epidemiol Biomarkers Prev 2004; 13:487–491.

    PubMed  CAS  Google Scholar 

  30. Standal T, Hjorth-Hansen H, Rasmussen T, et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma [J]. Haematologica 2004; 89:174–182.

    PubMed  CAS  Google Scholar 

  31. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer [J]. Proc Natl Acad Sci USA 2005; 102:7677–7682.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Institute, the First Affiliated Hospital, China Medical University, Shenyang, 110001, China

    Gong Yue-hua  (宫月华), Sun Li-**  (孙丽萍) & Yuan Yuan  (袁媛)

Authors
  1. Gong Yue-hua  (宫月华)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sun Li-**  (孙丽萍)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan Yuan  (袁媛)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuan Yuan  (袁媛).

Additional information

This work was supported by the National “973” Key Technologies R & D Program of China (2004BA703B04-02).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gong, Yh., Sun, Lp. & Yuan, Y. Serum pepsinogen and osteopontin for gastric cancer screening. Chin. J. Cancer Res. 19, 153–158 (2007). https://doi.org/10.1007/s11670-007-0153-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-007-0153-y

CLC number

Key words

Search

Navigation